This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Make each MenACWY
vaccination a MENVEO moment

Help protect appropriate adolescent patients with a primary and booster dose of MENVEO

Make each MenACWY vaccination a MENVEO moment.

Help protect appropriate patients with a primary and booster dose of MENVEO.

According to 2018 CDC data, only 51% of 17-year-olds received a primary
AND booster dose of MenACWY vaccine.
1 Do you incorporate the
CDC-recommended booster as part of your vaccination protocol?

In 2018, only 51% of 17-year-olds received a primary AND booster dose of MenACWY vaccine.1 Do you incorporate the CDC-recommended booster as part of your vaccination protocol?

MENVEO Dosing for Younger and Older Adolescents1
Primary Vaccination Booster Vaccination
Single dose in adolescents and adults aged 11 through 55 years Single booster dose may be administered to individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose of a MenACWY vaccine

INDICATION

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons aged 2 months through 55 years. MENVEO does not prevent N. meningitidis serogroup B infections.


Vaccination may not protect all recipients.

 

Help protect appropriate adolescent patients with a primary AND booster dose of MENVEO2

> EXPLORE MENVEO BOOSTER DATA

Hear a first-hand account from a physician who has seen meningococcal disease in the pediatric ICU.
 

> SEE ALL VIDEOS

Learn how to implement MENVEO into your practice and how to reconstitute and administer MENVEO.

> LEARN MORE

CDC=Centers for Disease Control and Prevention; ICU=intensive care unit; MenACWY=meningococcal serogroups A, C, W, Y.

References

  1. Centers for Disease Control and Prevention. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2018. MMWR. 2019;68(33):718-723.
  2. Prescribing Information for MENVEO.

INDICATION

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons aged 2 months through 55 years. MENVEO does not prevent N. meningitidis serogroup B infections.

IMPORTANT SAFETY INFORMATION FOR MENVEO

  • Severe allergic reaction (eg, anaphylaxis) after a previous dose of MENVEO, any component of this vaccine, or any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine is a contraindication to administration of MENVEO
  • Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of MENVEO
  • Syncope, sometimes resulting in falling injury associated with seizure-like movements, has been reported following vaccination with MENVEO. Vaccinees should be observed for at least 15 minutes after vaccine administration to prevent and manage syncopal reactions
  • Safety and effectiveness of MENVEO have not been evaluated in immunocompromised persons. If MENVEO is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer MENVEO to subjects with a known history of GBS should take into account the potential benefits and risks
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including MENVEO, to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
  • In clinical trials evaluating a primary vaccination dose or series, common solicited adverse reactions with MENVEO among children initiating vaccination at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea. Common solicited adverse reactions among children initiating vaccination at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea. Common solicited adverse reactions among children aged 2 years through 10 years who received MENVEO were injection-site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Some events were severe. In a clinical trial evaluating booster dose vaccination among adolescents and adults aged 15 through 55 years, similar rates of solicited adverse reactions were observed following a single booster dose. Common solicited adverse reactions were pain at the injection site and fatigue
  • Vaccination with MENVEO may not result in protection in all vaccine recipients

Trademarks are property of their respective owners.